Juvmo (Tavapadon): A New Once-Daily Treatment for Parkinson’s Disease
Parkinson’s disease (PD) is a progressive neurological disorder that affects movement, coordination, and other aspects of nervous-system function. Although levodopa remains an important treatment for Parkinson’s disease, many patients eventually experience changes in the amount of time their medication controls their symptoms, commonly described as “ON” and “OFF” periods. The development of additional treatments that can provide sustained symptom control is therefore an important area of Parkinson’s research. One of the newest medications in this area is Juvmo, whose active ingredient is tavapadon.
On September 25, 2026, the U.S. Food and Drug Administration (FDA) approved Juvmo for the treatment of Parkinson’s disease in adults. Tavapadon is a once-daily oral medication and is a selective partial agonist of the dopamine D1 and D5 receptor subtypes, making its mechanism different from traditional dopamine agonists that primarily target D2 and D3 receptors (U.S. Food and Drug Administration [FDA], 2026; AbbVie, 2026).
What Is Juvmo?
Juvmo contains tavapadon, a medication developed to stimulate specific dopamine receptors involved in motor control. The drug is classified as a selective D1/D5 dopamine receptor partial agonist. Dopamine signaling plays a central role in movement, and loss of dopamine-producing neurons is one of the major biological features of Parkinson’s disease.
Unlike traditional dopamine agonists such as pramipexole and ropinirole, which primarily stimulate D2-like receptors, tavapadon selectively acts on D1 and D5 receptors. Researchers developed this approach with the goal of improving motor symptoms while potentially reducing some adverse effects associated with broader dopamine-receptor stimulation (Pahwa et al., 2026; Fernandez et al., 2026).
The FDA-approved product is available as oral tablets. Juvmo includes 0.25-mg and 1-mg tablets in a titration pack and 5-, 10-, and 15-mg tablets for maintenance treatment.
How Does Tavapadon Work?
Parkinson’s disease is associated with degeneration of dopamine-producing neurons in the substantia nigra and reduced dopamine signaling within brain circuits involved in movement. This dopamine deficiency contributes to characteristic motor symptoms such as bradykinesia, rigidity, and tremor.
Tavapadon works by partially activating D1 and D5 dopamine receptors. These receptors belong to the D1-like family of dopamine receptors and participate in signaling pathways involved in motor function. Because tavapadon directly stimulates these receptors, it can provide dopaminergic activity without requiring the brain to produce normal amounts of dopamine.
The pharmacological approach is different from levodopa, which is converted into dopamine in the brain, and different from D2/D3-preferring dopamine agonists. The aim is to provide another way of restoring dopamine-related signaling relevant to movement control (Pahwa et al., 2026).
Who Can Use Juvmo?
The FDA indication is broad in the sense that Juvmo is approved for the treatment of Parkinson’s disease in adults. Clinical development studied tavapadon both as a treatment for people with relatively early Parkinson’s disease who were not receiving oral levodopa and as an add-on treatment for people already taking levodopa who experienced motor fluctuations (FDA, 2026; Fernandez et al., 2026).
The clinical studies therefore examined two important treatment situations. In early Parkinson’s disease, tavapadon was studied as monotherapy. In patients with more established disease and motor fluctuations, it was evaluated as adjunctive therapy added to oral levodopa. This makes Juvmo relevant to different stages of Parkinson’s disease management, although treatment should be individualized according to the patient's clinical status.
Juvmo has not been established as safe and effective in children. The FDA waived pediatric studies because Parkinson’s disease is not an indication that occurs in the pediatric population in the context of this application.
How Is Juvmo Dosed?
Juvmo is taken once daily, with or without food. Treatment begins with a low dose and is gradually increased during a titration period to improve tolerability. The manufacturer's dosing information describes a 40-day titration period before reaching the usual initial maintenance dose of 5 mg once daily. Depending on response and tolerability, the maintenance dose may subsequently be increased, with a maximum recommended dose of 15 mg once daily.
The gradual titration is important because dopaminergic medications can cause adverse effects, particularly when treatment is started or doses are increased. Patients should follow the prescribed titration schedule rather than increasing the dose independently.
Certain medications can also alter tavapadon concentrations. The current prescribing information includes recommendations concerning CYP3A inducers and inhibitors. Strong CYP3A inducers should be avoided, while certain CYP3A inhibitors and moderate inducers require dosage adjustments depending on the stage of treatment (AbbVie, 2026).
Evidence From the TEMPO-1 Trial
One of the major trials supporting tavapadon was TEMPO-1, a Phase 3 randomized, double-blind, placebo-controlled study involving adults with early Parkinson’s disease. Participants were randomized to receive fixed doses of tavapadon at 5 mg or 15 mg once daily or placebo for 27 weeks.
The study enrolled 529 participants. Both tavapadon doses produced statistically significant improvements in the combined Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Parts II and III compared with placebo. The 5-mg group had a 9.7-point decrease compared with a 1.8-point increase in the placebo group, while the 15-mg group had a 10.2-point decrease compared with a 1.8-point increase with placebo (Pahwa et al., 2026).
These findings suggest that tavapadon can improve motor symptoms and activities of daily living in people with early Parkinson’s disease. However, as with other short-term Phase 3 trials, the results demonstrate improvement during the study period rather than proving that the medication changes the underlying progression of Parkinson’s disease.
Evidence From the TEMPO-2 Trial
TEMPO-2 evaluated flexible-dose tavapadon in adults with early Parkinson’s disease. Participants received 5–15 mg once daily or placebo for 27 weeks. The primary outcome was the change in MDS-UPDRS Parts II and III.
Tavapadon produced a statistically significant improvement in the primary outcome compared with placebo. The least-squares mean change was a 10.3-point decrease with tavapadon compared with a 1.2-point decrease with placebo, corresponding to a treatment difference of approximately 9.1 points (Fernandez et al., 2026).
The study also provided important safety information. Adverse events were more frequent with tavapadon than placebo, particularly during the initial dose-titration period. Common adverse reactions included nausea, headache, dizziness, changes in taste, fatigue, vomiting, dry mouth, and anxiety (Fernandez et al., 2026; AbbVie, 2026).
Evidence From the TEMPO-3 Trial
TEMPO-3 examined tavapadon as an add-on to levodopa in adults with Parkinson’s disease who were experiencing motor fluctuations. This is an important clinical problem because the effects of levodopa may become less consistent as Parkinson’s disease progresses, resulting in periods when symptoms return before the next medication dose.
The study included 507 participants and compared flexible-dose tavapadon, at 5–15 mg once daily, with placebo over 27 weeks. Tavapadon increased daily “good ON-time”—time with better mobility without troublesome dyskinesia—by an additional 1.10 hours compared with placebo. It also reduced daily OFF-time by approximately 0.94 hours more than placebo (Fernandez et al., 2026).
These results suggest that tavapadon can provide additional motor control for some people whose symptoms fluctuate despite ongoing levodopa treatment. The trial does not mean that every patient will experience the same degree of improvement, and treatment response can vary considerably among people with Parkinson’s disease.
What Does “ON” and “OFF” Time Mean?
The terms “ON” and “OFF” are commonly used in Parkinson’s care to describe fluctuations in medication response. During an “ON” period, medication is providing adequate symptom control and movement may be easier. During an “OFF” period, Parkinson’s symptoms such as stiffness, slowness, tremor, or difficulty moving may return or become more pronounced.
Troublesome dyskinesia can also occur during periods when medication is working. Dyskinesia refers to involuntary movements that can develop in people receiving dopaminergic treatment, particularly after prolonged levodopa exposure.
An important outcome of the TEMPO-3 study was therefore not simply reducing OFF-time but increasing time spent in a better-controlled state without troublesome dyskinesia. This reflects the practical goal of improving daily functioning rather than focusing only on an individual neurological score (Fernandez et al., 2026).
Common Side Effects
Juvmo can cause adverse reactions, and the effects reported may differ depending on whether the medication is used alone or with levodopa. According to current product safety information, common adverse reactions when Juvmo is used without levodopa include nausea, headache, dizziness, fatigue, altered taste, vomiting, dry mouth, and anxiety. When used with levodopa, common adverse reactions include nausea, dyskinesia, dizziness, headache, hallucinations, and orthostatic hypotension (AbbVie, 2026).
Nausea is particularly relevant during dose escalation. Some patients may also experience dizziness or blood-pressure changes, particularly when standing. These symptoms can increase the risk of falling and should be discussed with a healthcare professional if persistent or severe.
Orthostatic Hypotension and Falls
Orthostatic hypotension occurs when blood pressure falls after standing, potentially causing dizziness, weakness, blurred vision, or fainting. Parkinson’s disease itself can affect autonomic blood-pressure regulation, and dopaminergic medications can further contribute to this problem.
Current Juvmo safety information advises monitoring for hypotension and orthostatic hypotension, especially during dose escalation. Patients are generally advised to change position slowly and report symptoms that could increase their risk of falling (AbbVie, 2026).
Fall prevention is particularly important in Parkinson’s disease because balance impairment may already be present. A medication-related increase in dizziness or blood-pressure instability can add another risk factor.
Hallucinations and Psychotic-Like Behavior
Dopaminergic medications can sometimes cause hallucinations or other changes in perception or behavior. Juvmo's prescribing information warns that hallucinations and psychotic-like behavior can occur, and that older patients may have an increased risk. The risk may also be affected by interactions with certain medications that increase tavapadon exposure (AbbVie, 2026).
People taking Juvmo should report new hallucinations, confusion, or unusual behavioral changes to their healthcare provider. Individuals with a history of psychotic disorders require particular clinical consideration because dopaminergic stimulation may worsen psychotic symptoms in susceptible patients.
Impulse-Control and Compulsive Behaviors
Another important safety issue is the possibility of impulse-control disorders or compulsive behaviors. Dopaminergic therapies for Parkinson’s disease can cause intense urges that may be difficult to control.
Juvmo's current safety information specifically identifies potential increases in gambling, sexual urges, uncontrolled spending, binge eating, compulsive eating, and other unusual urges. Healthcare professionals are advised to ask patients and caregivers about these behaviors because patients may not always recognize them as medication-related (AbbVie, 2026).
Recognizing these changes early is important because they can cause financial, relationship, occupational, or other serious consequences. Dose reduction or discontinuation may be considered by the treating clinician when clinically appropriate.
Dyskinesia
Dyskinesia refers to involuntary, uncontrolled movements and is a recognized complication of dopaminergic treatment in Parkinson’s disease. Juvmo may cause or worsen preexisting dyskinesia, particularly when it is used with levodopa.
The manufacturer advises that clinicians consider reducing the dose of Juvmo or adjusting other dopaminergic medications if dyskinesia develops or worsens (AbbVie, 2026).
The occurrence of dyskinesia does not necessarily mean that treatment must be abandoned, but it does mean that medication doses may need careful reassessment.
How Juvmo Differs From Traditional Dopamine Agonists
One of the most distinctive aspects of tavapadon is its receptor selectivity. Traditional dopamine agonists used in Parkinson’s disease, such as pramipexole and ropinirole, primarily target D2-like receptors. Tavapadon selectively acts as a partial agonist at D1 and D5 receptors.
Researchers developed this approach because D1-like receptor signaling is important in the neural circuits responsible for movement. The clinical development program sought to determine whether selective D1/D5 stimulation could provide meaningful motor improvement while offering a different adverse-effect profile from D2/D3 agonists (Pahwa et al., 2026; Fernandez et al., 2026).
However, the clinical data do not establish that tavapadon eliminates the adverse effects associated with dopaminergic therapy. Hallucinations, dyskinesia, orthostatic hypotension, impulse-control problems, and other adverse effects remain important considerations.
Juvmo and Levodopa
Juvmo does not replace the role of levodopa for every patient. Instead, it can be used as a standalone treatment in appropriate adults with Parkinson’s disease or as an adjunctive therapy to oral levodopa.
TEMPO-3 specifically demonstrated that adding tavapadon to stable levodopa treatment increased good ON-time and reduced OFF-time compared with placebo (Fernandez et al., 2026).
The medication therefore represents another tool for clinicians managing motor symptoms and fluctuations. The decision to use tavapadon alone, with levodopa, or alongside another therapy depends on factors such as disease stage, symptom pattern, treatment response, adverse effects, and other medical conditions.
Long-Term Evidence and Remaining Questions
The initial Phase 3 studies lasted approximately 27 weeks, providing strong evidence of short-term efficacy but less information about very long-term safety and effectiveness. An open-label extension study, TEMPO-4, has provided additional follow-up information, with the manufacturer reporting continued treatment effects through week 85. Because open-label extension studies do not maintain the same randomized blinded structure as the pivotal placebo-controlled trials, their findings should be interpreted more cautiously (AbbVie, 2026).
The FDA also required a postmarketing study to evaluate tavapadon's potential to induce CYP3A4 and its effect on other CYP3A4-substrate medications. The FDA's timetable calls for study completion in 2029, illustrating that important questions about drug interactions continue to be investigated after approval (FDA, 2026).
Another important unanswered question is whether tavapadon has any effect on the underlying progression of Parkinson’s disease. Current trials demonstrate symptomatic improvement. They do not establish that tavapadon slows or stops the neurodegenerative process responsible for Parkinson’s disease.
The Importance of Individualized Treatment
Parkinson’s disease varies considerably among individuals. Some people primarily experience tremor, whereas others have greater rigidity, bradykinesia, gait problems, balance difficulties, or cognitive and nonmotor symptoms. Medication response can also vary.
Consequently, the availability of Juvmo does not mean that it is appropriate for every person with Parkinson’s disease. Treatment decisions should consider current medications, age, cardiovascular status, blood-pressure problems, hallucinations, psychiatric history, impulse-control symptoms, fall risk, and the presence of motor fluctuations.
Regular follow-up is especially important during titration because many adverse effects are more likely to occur when the dose is being increased. Patients should not stop or change Juvmo abruptly without discussing the decision with their healthcare professional.
Conclusion
Juvmo (tavapadon) is a newly approved oral medication that expands the treatment options available for adults with Parkinson’s disease. FDA approval on September 25, 2026, established tavapadon as a selective D1/D5 dopamine receptor partial agonist for the treatment of Parkinson’s disease in adults (FDA, 2026).
The Phase 3 TEMPO program demonstrated improvements in motor symptoms among people with early Parkinson’s disease and increased good ON-time while reducing OFF-time when tavapadon was added to levodopa in patients experiencing motor fluctuations (Pahwa et al., 2026; Fernandez et al., 2026).
At the same time, Juvmo is a dopaminergic medication with important safety considerations. Nausea, dizziness, headache, fatigue, altered taste, vomiting, dry mouth, anxiety, dyskinesia, hallucinations, and orthostatic hypotension may occur depending on how the medication is used. Clinicians must also monitor for impulse-control or compulsive behaviors and changes in thinking or perception (AbbVie, 2026).
The arrival of tavapadon is significant because it provides a new pharmacological approach based on selective D1/D5 receptor stimulation. However, it should be viewed as an additional treatment option rather than a cure for Parkinson’s disease. Continued long-term research will be important for determining its safety, durability, drug-interaction profile, and role within comprehensive Parkinson’s disease care.
References
AbbVie Inc. (2026). Juvmo (tavapadon) prescribing information and healthcare professional information. https://www.juvmohcp.com/
Fernandez, H. H., Isaacson, S. H., Hauser, R. A., Agarwal, P., Ondo, W., Park, A., Kremens, D., Leoni, M., Duvvuri, S., Combs, C., Koenig, E., Chang, I., Pastino, G., Tringali, S., Golonski, N., Sanchez, R., Harmer, L., Boiser, J., Zadikoff, C., & Mari, Z. (2026). Tavapadon as adjunctive treatment for Parkinson disease: The TEMPO-3 randomized clinical trial. JAMA Neurology, 83(5), 442–451. https://doi.org/10.1001/jamaneurol.2026.0577
Fernandez, H. H., Bhatia, P., Cloud, L., Fietzek, U. M., Matarazzo, M., Molho, E., Peckham, E., Tarakad, A., Combs, C., Leoni, M., Chang, I., Tringali, S., Boiser, J., Sanchez, R., & Zadikoff, C. (2026). Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): A phase 3, randomised, placebo-controlled, double-blind trial. The Lancet Neurology, 25(8), 721–730. https://doi.org/10.1016/S1474-4422(26)00215-2
Pahwa, R., Moro, E., Espay, A. J., Dhall, R., Mari, Z., & colleagues. (2026). Fixed-dose tavapadon for early Parkinson disease: A randomized clinical trial. JAMA Neurology, 83(5), 452–460. https://doi.org/10.1001/jamaneurol.2026.0590
U.S. Food and Drug Administration. (2026, September 25). NDA 220415: Juvmo (tavapadon) approval letter. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220415Orig1s000ltr.pdf
U.S. Food and Drug Administration. (2026). Novel drug approvals for 2026. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
Comments